In the development of antibody-drug conjugates (ADCs), selecting an appropriate linker is a critical factor that determines the efficacy and safety of the final product.

BioAegis Therapeutics has initiated its Phase 2 clinical trial for Gelsolin, an immune modulator, by enrolling its first patient to address Acute Respiratory Distress Syndrome (ARDS).

Poseida Therapeutics focuses on developing unique non-viral therapies for individuals suffering from cancer, autoimmune disorders, and rare diseases.

The U.S. FDA has authorized VYALEV™ (foscarbidopa and foslevodopa) for adults with advanced Parkinson’s disease.

Response Pharmaceuticals has begun enrolling its first patients in a Phase 2 trial for RDX-002, a new small molecule iMTP inhibitor, targeting individuals stopping GLP-1 agonists.

Clarametyx Biosciences reveals advancements in research on CMTX-101 antibody treatment for cystic fibrosis-related infections.

Bright Peak Therapeutics has initiated dosing for the first patient in the Phase 1/2a clinical trial of BPT567, an innovative bifunctional PD1-IL18 immunoconjugate.

Wave Life Sciences reports the first successful therapeutic RNA editing in humans during the RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency.

Latigo Biotherapeutics has administered the first dose to a participant in its Phase 1 clinical trial for LTG-305, aimed at non-opioid pain management.

The role of Artificial Intelligence (AI) in the design of small nucleic acid drugs is becoming increasingly prominent.

IgGenix has reported that the initial patient has been dosed in its Phase 1 trial, named "ACCELERATE Peanut," which is testing IGNX001 for peanut allergies.

Ravulizumab is composed of two types of polypeptide chains, light and heavy chains, which are typical of monoclonal antibodies.